【Abstract】Objective To investigate the effect of urapidil combined with nifedipine on heparanase (HPA), advanced glycation end products (ages) and maternal and infant outcomes in patients with gestational hypertension. Methods200 patients with gestational hypertension admitted to our hospital from October 2017 to October 2018 were selected and divided into the observation group (n=105) and the control group (n=95) by the random number table method. The control group was treated with nifedipine, while the observation group was treated with urapidil combined with nifedipine. The clinical efficacy, serum HPA, AGEs, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) levels, maternal and child outcomes and adverse reactions were compared between the two groups.Results After treatment, the total effective rate of the observation group (9619%) was significantly higher than that of the control group (7684%) (P＜005). Before treatment, there was no significant difference in serum HPA and AGEs between the two groups. After treatment, serum HPA and AGEs levels in both groups were improved, and HPA and AGEs levels in the observation group were significantly lower than those in the control group (P＜005). Before treatment, there was no significant difference in blood pressure between the two groups. After treatment, blood pressure levels in both groups were improved, and SBP, DBP and MAP levels in the observation group were significantly lower than those in the control group (P＜005). The total incidence of neonatal death, asphyxia, postpartum hemorrhage and preterm delivery in the observation group was 667%, significantly lower than that of the control group (3895%), with significant differences (P＜005). The total incidence of adverse reactions in the two groups was 1429% and 2316%, with no significant difference (P＞005). Conclusion Urapidil combined with nifedipine has a significant effect in patients with gestational hypertension, which can effectively improve HPA, AGEs and maternal and infant outcomes, without increasing adverse reactions.